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As novel heat shock protein 70 (HSP70) inhibitors, N, N0-disubstituted thiourea derivatives were
designed and synthesized based on the X-ray structure of the ATPase domain (nucleotide binding
domain, NBD). An ATPase activity inhibition assay revealed that these compounds effectively inhibited
HSP70 ATPase activity. The results revealed that the compounds 370/371/374/379/380//392/394/397/
404/405 and 407 can inhibit the HSP70 ATPase turnover with high percentages of inhibition: 50.42,
38.46, 50.45, 44.12, 47.13, 50.50, 40.95, 65.36, 46.23, 35.78, and 58.37 in 200 mM, respectively. Signiﬁcant
synergies with lapatinib were observed for compound 379 and compound 405 in the BT474 breast cancer
cell line. A structure-function analysis revealed that most of the thiourea derivatives exhibited cooper-
ative action with lapatinib in the BT474 cancer cell line and the BT/LapR1.0 lapatinib-resistant cell line.
HSP70 inhibitors may be developed as synergetic drugs in drug-resistant cancer therapy.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As awidely present molecular chaperone, heat-shock protein 70
(HSP70) plays important roles in the stabilization of vital proteins.
HSP70 is involved in numerous cellular activities, such as the
folding of newly synthesized proteins, the subcellular transport of
proteins and vesicles [1], the maturation of intracellular proteins
[2]and the degradation of misfolded proteins [3]. Therefore, the
regulation of HSP70 enzymatic activities has become crucial to
controlling cell growth and metabolic functions [4].
Although HSP70 exists in almost all living organisms, it is
typically highly expressed and activated in cancer cells [5]. High
levels of HSP70 in cancer cells are related with the resistance to cell
death induced by heat, UV radiation, tumour necrosis factor (TNF),
caspase-3 overexpression, oxidative stress, and several chemo-
therapeutic drugs [6e9]. At the pro-mitochondria level, HSP70
blocks the maturation of procaspase-3 and procaspase-7 to inhibit
the protease-dependent apoptosis signal pathway [10]. At the
mitochondrial level, HSP70 inhibits Bad and/or Bax and keeps them
from translocating to the mitochondria to prevent mitochondrialgwu@bmi.ac.cn (W. Zhong).
Masson SAS. This is an open accessouter membrane permeabilization and inhibit the release of cyto-
chrome c, which acts upstream of mitochondrial membrane de-
polarization [10], and apoptosis inducing factor (AIF) to maintain
the mitochondrial membrane potential [11]. At the post-
mitochondrial level, it inhibits apoptosis through the release of
cytochrome c and the activation of caspase-3 to prevent the
recruitment of procaspase-9 to the apoptosome by directly binding
to Apaf-1 [12], which prevents the formation of the active apop-
tosome. At the receptor level, HSP70 may promote receptor-
mediated apoptosis. HSP70 mediates the Bcr-Abl-induced resis-
tance to TNF-a-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis by preventing the formation of death-inducing signalling
complexes involving the death receptors DR4 and DR5 [13]. In
addition, HSP70 interacts with the Fanconi Anaemia Complemen-
tation Group C (FANCC) protein via its ATPase domain, and together
with HSP40, it inhibits TNF-induced apoptosis through the ternary
complex of HSP70, FANCC, and PKR (Fig. 1) [14,15].
It's reported that targeting the testis-speciﬁc heat-shock protein
70-2(HSP70-2) can reduces cellular growth, migration, and inva-
sion in renal cell carcinoma cells [16]. Although the efﬁcacy of
HSP70 inhibitors as a single-agent therapy is limited due to their
pharmacological and pharmacodynamic properties, they have been
reported to enhance the cytotoxic activity of various antitumour
agents [17]. The effect of a combination of HSP70 inhibitors witharticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Anti-cancer pathway.
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recent preclinical and clinical studies, which demonstrated the
synergic effects of HSP70 inhibitors in most cases [18]. Blocking the
function of both heat shock protein 90 and 70 simultaneously limits
these chaperones' cytoprotective effects on cancer cells. And the
unique phenotype associatedwithmodulating Hsp90's C-terminus,
a synergistic and highly relevant dual chemotherapy regimen was
produced when it used in combination with Hsp70 inhibitors [19].
The inhibition of HSP70 in cancer cells may reduce the incidence of
drug resistance. In this study, we aimed to design a series of novel
HSP70 inhibitors that exert synergic effects with anticancer agents.
2. Computational methods
All members of the Hsp70 family have an N-terminal nucleotide
binding domain (NBD) (~40 kDa) and a C-terminal substrate-
binding domain (SBD) (~25 kDa) connected by a short linker
(Fig. 2). The X-ray structure of HSP70 NBD in complex with ADP
(PDB ID: 3I33) from the Brookhaven Protein Data Bank (http://
www.rscb.org/pbd/) was used for virtual screening using the
DOCK4.0 software. The database originated from ACD and our
patented compound library. The target protein was prepared usingFig. 2. Three-dimensional structure of HSP70.the Chimera software. The grid-based energy scoring function was
used to evaluate the afﬁnity of the designed inhibitors to HSP70.
The energy scoring component of DOCK 4.0 was based on the
implementation of force ﬁeld scoring. Force ﬁeld scores are
approximate molecular mechanics interaction energies consisting
of van der Waals and electrostatic components:
DGbinding z DHbinding. An anchor-ﬁrst search was used for the
small-molecule-conformation search. The optimized fragments
were selected by critical site point matching, chemical matching
and energy minimization. Ultimately, the top 1000 molecules were
selected. More extensive docking was performed using MVD (Mo-
lecular Virtual Docker, Version 2010.4.0) with ADP as the ligand
template. Hydrogen bonds were formed between ADP and the
amino acid residues Thr15, Tyr16, Gly205, Glu271, Lys274, Ser278,
Gly342, and Arg345 (Fig. 3). The energy grid used a 0.4-Å resolu-
tion. The MolDock score [Grid] was chosen as the scoring function
with 0.3-Å resolution. Based on the current resolution and the
search space size, the grid requires approximately 46.7 MB of
memory. The number of maximal iterations, maximal population
size, and the numbers of pose generations, simplex evaluations, and
docking runs were set to 1500, 50, 100, 300, and 10, respectively.
Several structural units were selected. Among them, the N, N0-
disubstituted thiourea derivatives (Fig. 4) from our patented com-
pound library (Patent CN103387551A) were themost attractive due
to their perfect binding results. For example, hydrogen bonds were
formed between compound PP1-051 (Fig. 3) and the amino acid
residues Thr14, Thr15, Gly205, Gly206 and Thr207. The binding
proﬁles of some of the compounds to HSP70 were almost similar to
that found for ADP.
This series of compounds from our patented compound library
have been reported to be used for the protection of cells from
apoptosis induced by endoplasmic reticulum (ER) stress [20].
Moreover, it has been revealed that the trichloromethyl group
greatly contributes to the activity. Therefore, we designed and
prepared novel N, N0-disubstituted thiourea derivatives as HSP70
inhibitors by changing the R3 from CX3 to a short-chain fatty acid to
establish a peptidomimetic effect (Fig. 5).
The modelled structures of the newly designed molecules were
computationally docked into the crystal structure of the HSP70
Fig. 3. Schematic of the residues that interact with PP1-051. The ﬁgure was produced using the LigPlus program. Hydrogen bonds are indicated by dashed lines between the atoms
involved, whereas hydrophobic contacts are represented by an arc with spokes radiating toward the contact site. The contact atoms are shown with spokes radiating back. The
HSP70 residues are identiﬁed by the three-letter amino acid codes. Colour coding: ligand residue names, blue; hydrophobic residue names, black; ligand bonds, purple; non-ligand
bonds, orange; hydrogen bonds, olive green; and hydrophobic “bonds”, brick red. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
Fig. 4. Screened nuclear structure from our database.
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Fig. 5. CX3 was changed to a short-chain fatty acid.
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protocol based on the Sybyl6.9 software and the scoring function
grid score. As shown in Fig. 6A and B, the docking results of com-
pound 371 and compound 375 revealed several key amino acid
residues in the binding pocket, such as Thr15, Arg275 and Asp369.
3. Results and discussion
3.1. Chemistry
The compounds 370e409 were synthesized as shown in
Scheme 1. The reaction of a commercially available aldehyde (1)
with malonic acid yielded an a, b-unsaturated acid (2) via an aldol
condensation reaction, and this compound was then reacted with
4-methylbenzoyl chloride to yield the product (3). Substituted a, b-
unsaturated amides (4) were obtained via an aminolysis reaction of
product (3) with concentrated ammonia in chloroform. The reac-
tion of a, b-unsaturated amides (4) with the fatty aldehyde and
benzotriazole in the presence of p-toluenesulphonic acid produced
benzotriazole intermediates (5) [21], which were coupled with
amines (8) to yield the desired products, as shown in Table 1. The
intermediate (8) was acquired by the treatment of product (7) with
concentrated ammonia in methanol. The reaction of ammonia with
carbon disulphide andmethyl iodide in DMSO yielded intermediate
(7).
3.2. Colorimetric determination of HSP70 ATPase activity
In the preliminary screening system, the compounds that were
found to inhibit HSP70 ATPase activity by 20% at the concentration
of 200 mMwere deﬁned as effective inhibitors [22,23]. Two positiveFig. 6. Docking-predicted binging poses of compound 371 (Fig. 6A) and compound 375 (Fig.
were created using the PyMol software.control compounds were applied to verify the accuracy of the
screening system. The inhibition rate of the control compounds AZ
[23] and VER155008 [22] reached 53.13% and 43.03%, respectively,
indicating the high efﬁcacy and accuracy of the experimental
system.
Dose-dependent effects were observed for AZ and VER155008
(positive control) when these were incubated at multiple concen-
trations (200 mM, 100 mM, 50 mM, 25 mM, and 12.5 mM) with HSP70
(Fig. 7). The compounds 370/371/374/379/380/392/394/397/404/
405 and 407 were identiﬁed as potential inhibitors because their
inhibition rates were greater than 20% in multiple experiments
(Table 2, Fig. 8).3.3. Resistance reversal test to lapatinib
All of the compounds were tested to determine their drug
resistance reversal effect to lapatinib in vitro. The luminescent
signal indicating the ATP level was measured, and the data were
normalized to that obtained for the control group. The cell viability
was determined by the luminescence: cell viability
(%) ¼ RLUexperimental group/RLUblank control group  100%. Simulta-
neously, the coefﬁcient of drug interaction (CDI) [24,25] was used
for the quantiﬁcation of the drug-interaction properties: CDI ¼ AB/
(A  B)  100%, based on the cell viability. A synergetic effect was
deﬁned as CDI< 1, and a signiﬁcant synergetic effect was deﬁned as
CDI< 0.7. The inhibition rates of the thiourea derivatives 370e409
for BT474 breast cancer cells and BT/LapR1.0 lapatinib-resistant
cells are shown in Table 3. No inhibition of BT474 and BT/LapR1.0
was observed when the HSP70 inhibitors were administered
independently (Table 3), but signiﬁcant synergies were observed
when compound 379 and compound 405 were administered6B). The interactions were analysed through computational docking, and the diagrams
Scheme 1. Synthetic pathways for N, N0-disubstituted thiourea derivatives 370e409. Reagents and conditions: a: malonic acid, pyridine, piperidine, reﬂux, 6 h; b: p-toluenesul-
phonyl chloride, Cl2CH2, tetramethylammonium bromide (TMAB), K2CO3; c: NH3$H2O, DAEI, DCM; d: (1) benzotriazole, R3CHO, toluene, reﬂux, 12 h; e: (1) R2NH2, CS2, DMSO, 60 C,
6 h; (2) ICH3, rt, 10 h; f: NH3$H2O, MeOH, reﬂux, 2 h; g: NaH, THF, rt, 1 h.
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tively (Table 4, Fig. 9A and D). Synergies effects were also observed
for the compounds 393/394/406 in BT/LapR1.0 cells (Table 5). Most
of the thiourea derivatives showed cooperative action with lapati-
nib in BT474 and BT/LapR1.0 cells (CDI< 1) (Figs. 10 and 11).
4. Conclusions
In this study, synergistic effects with an anti-cancer agent were
veriﬁed in vitro for N, N0-disubstituted thiourea derivatives, which
may reduce the dose of the anti-cancer agent, thereby abating its
toxicity or drug resistance during cancer treatment. Compound 379
and compound 405 presented signiﬁcant synergy with lapatinib in
the BT474 cell line with CDI values of 0.65 and 0.56, respectively
(Table 4). The compounds 393/394/406 showed a minor synergistic
effect in BT/LapR1.0 cells. Therefore, some of the novel HSP70 in-
hibitors were found to have obvious clinical signiﬁcance. In addi-
tion, the inhibition activities of the compounds 370/371/374/379//
380/392/394/397/404/405 and 407 were demonstrated through
in vitro zymological experiments, and these results suggested that
the synergetic effects are related to the inhibition of HSP70 activity.
However, the underlying mechanism remains to be elucidated.
X-ray crystal structures of HSP70 (3I33)were used for the design
and docking of the HSP70 inhibitors; thus, more detailed infor-
mation on the relationship between the inhibitor structures and
functions was obtained. This information may be important for the
development of effective HSP70 inhibitors. Through the determi-
nation of their therapeutic synergism and HSP70 ATPase activity,
we can better explore how those compounds enhance the thera-
peutic effect of anti-tumour agents via interacting with HSP70 and
thus develop more favourable drugs.
5. Materials and methods
5.1. Chemistry
The 1H NMR spectra were recorded in DMSO-d6 using a Bruker-
ARX400 spectrometer with TMS as the internal standard. All
chemical shifts are presented in d values (ppm). The MS spectra
were recorded using a Micromass ZabSpect. Elemental analyses
were performed with an Elementar Vario MICRO CUBE (Germany).5.2. Compounds
5.2.1. Synthesis of N, N0-disubstituted thiourea derivatives 370-409
General procedures: Aromatic formaldehyde (10 mmol) and
malonic acid (30 mmol) were stirred in dry pyridine (20 mL) for 8 h
with one drop of piperidine as the catalyst. Themixturewas poured
into 20 mL of water, and 10% NaOH (aq) was used to adjust the pH
to 12. After three extractions with ethyl acetate, 2 N HCl (aq) was
added to the water layer until a white precipitate (2) appeared in
85% yield.
Intermediate 2: (E)-3-(3, 4, 5-trimethoxyphenyl)acrylic acid. 1H
NMR (400 MHz, CDCl3-d)d3.90 (s, 9H); d6.35e6.39 (d, 1H,
J ¼ 16 Hz); d6.79 (s, 2H); d7.69e7.73 (d, 1H, J ¼ 16 Hz).
The white precipitate (2, 20 mmol) was dissolved in dry DCM
(30 mL). p-Toluenesulphonyl chloride (22 mmol), tetramethy-
lammonium bromide (10mmol) and K2CO3 (20 mmol) were added,
and the mixture was reﬂuxed for 40 min. The solvent was removed
under reduced pressure. Ten millilitres of methanol was added to
the resulting residue, and the mixture was stirred for 5 min. The
white solid (3) that precipitated from the solution was collected by
ﬁltration and washed with methanol. The white solid (15 mmol)
and DIEA (20 mmol) in DCM (20 mL) were stirred, and NH3$H2O
(40 mmol) was added. The mixture was then reﬂuxed at 6 h.
Saturated sodium bicarbonate solution (20 mL) was added to the
solution and extracted with DCM (20 mL  5). The organic phase
was collected, washed with brine (20 mL  3), dried over Na2SO4
and concentrated under reduced pressure to obtain the desired
product (4) in 80% yield.
Intermediate 4: (E)-3-(3, 4, 5-trimethoxyphenyl)acrylamide. 1H
NMR (400 MHz, CDCl3-d)d3.89 (s, 9H); d5.66 (s, 2H); d6.36e6.40 (d,
1H, J ¼ 15.6 Hz); d6.75 (s, 2H); d7.55e7.59 (d, 1H, J ¼ 15.6 Hz).
MS238.2 [MþH]þ.
A suspension of the product (4, 8 mmol), the corresponding
aldehyde (16 mmol) and benzotriazole (24 mmol) in toluene
(30 mL) was treated with concentrated HCl (nine drops). The so-
lution was heated at reﬂux under DeaneStark conditions for 20 h,
cooled to ambient temperature, and concentrated under reduced
pressure. Twenty millilitres of methanol was added, and the
mixture was stirred for 5 min. The white precipitate that was
formed was collected by ﬁltration and washed with 50% ether/
hexanes (20 mL) to provide the desired product (5) as a white solid
Table 1
Structures of N, N0-disubstituted thiourea derivatives 370e409a.
ID R1 R2 R3 Melting point (C) ID R1 R2 R3 Melting points (C)
370 105e108 389 174e176
371 159e162 390 166e168
372 175e178 391 90e92
373 173e174 392 206e208
374 148e150 393 H-393
375 168e170 394 168e170
376 222e224 395 119e121
378 115e117 396 182e184
379 168e169 397 188e190
380 115e117 402 97e100
381 186e189 404 180e182
382 216e219 405 182e184
383 146e150 406 166e168
384 195e198 407 138e141
386 152e155 408 174e176
387 120e122 409 192e194
388 178e180
a All of those compounds are white solid.
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Intermediate 5: (E)-N-(1-(1H-benzo[d] [1,2,3]triazol-1-yl)-2,2-
dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide: MS 425.5
[MþH]þ. (E)-N-(1-(1H-benzo[d] [1,2,3]triazol-1-yl)-3-
methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide: MS425.5
[MþH]þ. N-(1-(1H-benzo[d] [1,2,3]triazol-1-yl)-3,3-dimethylbutyl)
cinnamamide: MS349.5 [MþH]þ. N-(1-(1H-benzo[d] [1,2,3]triazol-
1-yl)-3-methylbutyl)cinnamamide: MS335.2 [MþH]þ. N-(1-(1H-benzo[d] [1,2,3]triazol-1-yl)-2,2-dimethylpropyl)cinnamamide:
MS 335.3 [MþH]þ.
DMSO (15 mL) and KOH (11 mmol) were added to a round-
bottomed ﬂask and cooled to 0 C. To this solution, carbon disul-
phide (15 mmol) was added, and the mixture was stirred for
10 min. The amine (10 mmol) in DMSO (5 mL) was then added
dropwise for 20e30 min with constant stirring, and the mixture
was then heated to 60 C for 6 h and cooled to room temperature.
Fig. 7. Percentage of inhibition of HSP70 ATPase activity achieved by the positive controls VER 155008 and AZ at different concentrations.
Table 2
Inhibition of HSP70 ATPase activity by the tested compounds at a concentration of
200 mM.
ID Percent inhibition (%) SD
AZ 53.04 0.89
VER155008 43.03 3.01
370 50.42 3.92
371 38.46 5.65
374 50.45 13.04
379 44.12 1.95
380 47.13 1.72
392 50.50 1.01
394 40.95 5.00
397 65.36 8.30
404 46.23 5.81
405 35.78 14.98
407 58.37 9.22
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temperature for 10 h. Water (50 mL) was added to the solution and
extracted with DCM (30 mL  3). The organic phase was collected,
washed with brine (20 mL  3), dried over Na2SO4 and concen-
trated under reduced pressure to obtain the desired product (7) inFig. 8. Percentage of inhibition of HSP70 ATPase activity achie55%e82% yield.
Intermediate 7: methyl phenylcarbamodithioate. 1H NMR
(400 MHz, CDCl3-d) d2.69 (s, 3H); d7.10e7.13 (t, 2H); d7.30e7.34 (t,
2H); d7.38e7.40 (d, 1H); d9.69 (s, 1H). Methyl pyridin-3-
ylcarbamodithioate: 1H NMR (400 MHz, DMSO-d6) d2.69 (s, 3H);
d7.38e7.42 (t, 2H, J ¼ 8.12 Hz and 4.76 Hz); d8.22 (s, 1H);
d8.52e8.53 (dd, 1H, J ¼ 4.76 Hz and 1.12 Hz); d8.71e8.72 (d, 1H,
J ¼ 2.52 Hz); d9.03 (s, 1H).
A solution of 8 (5 mmol) in methanol (10 mL) was treated with
concentrated ammonia (10 mmol). The mixture was heated at
reﬂux for 2 h, concentrated under reduced pressure, and extracted
with DCM and water (three times), and the organic phase was then
collected, washed with brine (20 mL  3), dried over Na2SO4 and
concentrated under reduced pressure to obtain the desired product
(8) in 80%e90% yield.
Intermediate 8: Phenylthiourea. 1H NMR (400 MHz, CDCl3-d)
d7.10e7.13 (t, 2H); d7.30e7.34 (t, 2H); d7.38e7.40 (d, 1H); d9.69 (s,
1H). MS153.0 [MþH]þ. 1-(pyridin-3-yl)thiourea: 1H NMR
(400 MHz, DMSO-d6)d7.34e7.37 (dd, 2H, J ¼ 8.44 Hz and 4.76 Hz);
d7.93e7.95 (d, 1H, J ¼ 8.12 Hz); d8.30e8.31 (dd, 1H, J ¼ 4.52 Hz and
1.12 Hz); d8.54e8.55 (d, 1H, J ¼ 2.8 Hz); d9.79 (s, 1H). MS154.0
[MþH]þ. 1-(pyridin-2-yl)thiourea: 1H NMR (400 MHz, CDCl3-d)ved by the test compounds at a concentration of 200 mM.
Table 3
Inhibition of the breast cancer cells BT474 and BT/LapR1.0 by the N, N0-disubstituted
thiourea derivatives 370e409.
ID Inhibition (%) of BT474 Inhibition (%) of BT/LapR1.0
10 mM 10 mM þ 1 mM lapatinib 10 mM 10 mM þ 1 mM lapatinib
370 7.3 76.6 9.4 42.2
371 9.2 79.1 10.5 54.2
372 2.2 83.2 2.9 48.8
373 10.3 84.7 16 56
374 12.2 85.2 13.7 56
375 8.6 85.2 12.3 55.7
376 20.1 87.8 17.4 59.6
378 24.9 87.8 38.7 61
379 19 90.9 40.9 62.3
380 22.1 89.9 19.3 59.9
381 25.8 88.5 31.5 65.9
382 12.4 86.2 18.2 57.6
383 4.8 79.1 11.4 32.8
384 2.4 78.8 6 25.2
386 17.7 85 13.6 36.9
387 11.3 84.9 34.6 53
388 9.6 83.5 11.4 33
389 3.8 81.4 8.7 27.8
390 9.4 82 11.5 30
391 10.5 79.8 13 30.9
392 8.2 81.4 9.9 30.1
393 44 87.4 6.8 44.2
394 18.2 84.2 18.9 41
395 9.8 81.6 12.8 23.3
396 7 78.7 9.7 20.5
397 6 78.6 8.7 20
402 11.5 78.5 15.4 23.4
404 16.5 83.4 38.8 48.1
405 13.5 87.3 39.8 57.8
406 15.3 82.2 22.6 45.7
407 13.5 84 19.8 33.4
408 10.3 80.6 13.3 75.8
409 13 85.2 34.3 47.2
Note: The administration of lapatinib at a concentration of 1 mM resulted in inhi-
bition percentages of 75.6% and 18% on the breast cancer cells BT474 and BT/LapR1.0,
respectively.
Table 4
CDI values of N, N0-disubstituted thiourea derivatives for BT474 cells.
ID BT474 (CDI) ID BT474 (CDI)
379 0.65 395 0.84
380 0.81 404 0.73
386 0.86 405 0.56
387 0.79 406 0.82
388 0.85 407 0.77
394 0.74 409 0.77
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d7.66e7.70 (m, 1H); d8.22e8.23 (dd, 1H, J ¼ 5.08Hzv); d9.15 (s, 1H);
d11.10 (s, 1H). MS154.0 [MþH]þ. 1-(4-methoxyphenyl)thiourea:
MS182.8 [MþH]þ.
Compounds 8 (2 mmol) and 5 (2 mmol) in THF (5 mL) were
added to NaH (2.4 mmol) in one portion. The mixturewas stirred at
room temperature for 1 h, extracted three times with ethyl acetate,
washed twice with saturated sodium chloride, dried over anhy-
drous sodium sulphate, and concentrated to yield a residue that
was chromatographed (ethyl acetate:petroleum ether ¼ 1:1) to the
pure product 370e409 in 55%e76% yield.
5.2.1.1. (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-
trimethoxyphenyl) acrylamide (370). 1H NMR (400 MHz, DMSO-d6)
d0.90e0.94 (m, 6H); d1.48e1.71 (m, 4H); d3.68 (s, 3H); d3.80 (s,
6H); d6.48e6.52 (d, 2H); d6.86 (s, 2H); d7.02 (s, 1H); d7.38e7.48 (m,
4H); d8.08 (s, 1H). 13CNMR (DMSO, 100 MHz) d21.88; 24.40; 42.88;
55.86; 59.56; 60.12; 105.04; 119.68; 121.40; 122.95; 124.21; 128.53;130.29; 138.76; 139.29; 139.40; 153.10; 164.75; 179.39. MS 458.4
[MþH]þ.
5.2.1.2. (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-
(3,4,5-trimethoxyphenyl) acrylamide (371). 1H NMR (400 MHz,
CCl3D-d6) d0.94 (s, 6H); d1.71e1.48 (m, 3H); d3.80 (m, 1H);
d3.87e3.89 (s, 10H); d5.66 (s, 1H); d6.39e6.43 (d, 1H, J ¼ 15.68 Hz);
d6.75 (s, 2H); d6.92e6.94 (d, 1H, J ¼ 6.2 Hz); d7.04e7.07 (d, 1H,
J ¼ 8.96 Hz); d7.30e7.33 (q, 1H, J ¼ 8.4 Hz and 4.76 Hz); d7.65e7.67
(d, 1H, J ¼ 15.68 Hz); d8.21e8.23 (d, 1H, J ¼ 7 Hz); d8.41e8.43 (dd,
1H, J ¼ 6.2 Hz and 1.44 Hz); d8.82 (s, 1H); d10.95 (s, 1H). 13C NMR
(CD3OD, 100 MHz) d21.96; 25.49; 42.86; 43.24; 56.11; 58.46; 60.65;
105.90; 118.29; 124.25; 131.34; 132.73; 138.28; 143.43; 145.15;
145.32; 154.24; 169.18; 182.02. MS 459.6 [MþH]þ.
5.2.1.3. (E)-N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)-3-(3,4,5-
trimethoxyphenyl) acrylamide (372). 1H NMR (400 MHz, DMSO-d6)
d0.87e0.96 (m, 9H); d3.68 (s, 3H); d3.80 (s, 6H); d6.14 (s, 1H);
d6.60e6.62 (d, 1H); d6.91 (s, 2H); d7.12e7.13 (t, 1H); d7.31e7.35 (t,
3H); d7.52e7.54 (d, 2H); d7.62 (d, 1H); d8.11 (s, 1H); d9.85 (s, 1H).
13CNMR (CD3OH, 100 MHz) d21.88; 24.40; 42.88; 56.13; 60.67;
105.04; 120.35; 121.40; 122.95; 124.21; 128.53; 131.55; 138.76;
140.25; 140.19; 154.26; 170.41; 180.09. MS 458.6 [MþH]þ.
5.2.1.4. (E)-N-(2,2-dimethyl-1-(3-pyridin-3-ylthioureido)propyl)-3-
(3,4,5-trimethoxyphenyl)acrylamide (373). 1H NMR (400 MHz,
CCl3D-d) d0.90e1.15 (s, 9H); d3.84e3.90 (s, 9H); d5.42 (m, 1H);
d6.44e6.46 (m, 1H); d6.49e6.53 (d, 1H); d6.64e6.66 (d, 1H); d6.78
(s, 2H); d7.29e7.32 (q, 1H, J¼ 8.2 Hz, J¼ 4.76 Hz); d7.69e7.73 (d, 1H,
J ¼ 7.84 Hz); d8.26e8.42 (d, 1H, J ¼ 7.84 Hz); d8.42e8.43 (dd, 1H,
J¼ 4.76 Hz, J¼ 1.4 Hz); d8.74e8.75 (d,1H, J¼ 1.96 Hz; d10.55 (s,1H).
13C NMR (DMSO, 100 MHz) d25.45; 55.81; 59.98; 66.16; 104.97;
121.40; 122.91; 130.04; 130.42; 136.49; 138.72; 139.23; 144.25;
144.71; 152.98; 164.18; 181.11. MS 459.4 [MþH]þ.
5.2.1.5. (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-
trimethoxy-phenyl)acrylamide (374). 1H NMR (400 MHz, DMSO-d6)
d0.91 (m, 1H); d2.05e2.07 (m, 2H); d3.75 (s, 4H); d3.79e3.80 (m,
2H); d3.88 (s, 6H); d6.03 (m, 1H); d6.71e6.75 (d, 1H); d7.03 (s, 2H);
d7.16e7.22 (m, 1H); d7.36e7.40 (t, 2H); d7.59e7.61 (d, 2H); d9.24 (s,
1H); d10.60 (s, 1H). 13CNMR (DMSO,100MHz) d15.26; 55.84; 60.02;
62.93; 105.10; 120.90; 122.95; 124.13; 128.34; 128.47; 130.26;
138.87; 139.34; 153.02; 164.71; 179.39. MS 442.4 [MþH]þ.
5.2.1.6. (E)-N-(cyclopropyl(3-pyridin-3-ylthioureido)methyl)-3-
(3,4,5-trimethoxyphenyl) acrylamide (375). 1H NMR (400 MHz,
CCl3D-d) d0.51e0.57 (m, 4H); d1.25e1.26 (m, 1H); d2.45 (s, 1H);
d3.87 (s, 9H); d4.99 (s, 1H); d6.43e6.47 (d, 1H); d6.74 (s, 1H);
d7.27e7.31 (m, 2H); d7.41e7.43 (d, 1H, J ¼ 8.4 Hz); d7.63e7.67 (d,
1H); d8.18 (s, 2H); d8.39e8.40 (d, 1H); d8.79 (s, 1H); d10.78 (s, 1H).
13C NMR (DMSO, 100 MHz) d15.57; 56.15; 60.42; 63.35; 105.32;
121.55; 123.40; 130.65; 136.50; 139.06; 139.65; 144.78; 145.27;
153.38; 164.33; 180.27. MS 443.5 [MþH]þ.
5.2.1.7. (E)-N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)-3-
(3,4,5-trimethoxyphenyl) acrylamide (376). 1H NMR (400 MHz,
DMSO-d6) d0.45e0.50 (m, 4H); d1.45e1.47 (m, 1H); d3.68 (s, 3H);
d3.81 (s, 6H); d5.92e5.94 (m, 1H); d6.55e6.59 (d, 1H, J ¼ 15.68 Hz);
d6.91 (s, 1H); d7.06e7.09 (m, 1H); d7.17e7.19 (d, 1H, J ¼ 8.4 Hz);
d7.37e7.41 (d, 1H, J ¼ 15.68 Hz); d7.79e7.80 (m, 1H); d8.24e8.26 (d,
1H, J¼ 1.4 Hz and 5.04 Hz)d8.61e8.63 (d, 1H, J¼ 7.84 Hz); d10.66 (s,
1H); d12.17e12.19 (d, 1H, J ¼ 8.12 Hz). 13C NMR (DMSO, 100 MHz)
d1.60; 2.07; 15.41; 55.84; 60.11; 63.09; 104.93; 112.74; 118.06;
121.29; 130.46; 138.65; 139.15; 139.55; 145.64; 153.07; 153.68;
164.29; 178.93. MS 443.3 [MþH]þ.
Fig. 9. CDI values of the compounds 379, 394, 404 and 405 for BT474 cells.
Table 5
CDI values of N, N0-disubstituted thiourea derivatives for BT/LapR1.0 cells.
ID BT/LapR1.0 (CDI) ID BT/LapR1.0 (CDI)
393 0.79 405 0.86
394 0.79 406 0.8
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(3,4,5-trimethoxyphenyl)acrylamide (378). 1H NMR (400 MHz,
CCl3D-d) d1.00e1.01 (s, 6H); d1.73e1.76 (m, 2H); d2.16 (s, 2H); d3.87
(s, 9H); d5.88 (s, 1H); d6.32e6.36 (d, 1H, J ¼ 15.74 Hz); d6.71e6.76
(m, 3H); d6.98e7.00 (m, 1H); d7.09 (m, 1H); d7.51e7.55 (d, 1H,
J ¼ 15.74 Hz); d7.64 (m, 1H); d8.24e8.25 (m, 1H); d10.32 (s, 1H).
13CNMR (DMSO, 100 MHz) d21.84; 22.96; 24.54; 42.94; 55.84;Fig. 10. Coefﬁcient of drug interaction (CDI) of thiourea d60.09; 104.94; 112.64; 117.94; 121.24; 130.37; 138.67; 139.05;
139.58; 145.59; 153.07; 153.72; 164.53; 178.32. MS 459.2 [MþH]þ.
5.2.1.9. (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-
trimethoxyphenyl)acrylamide (379). 1H NMR (400 MHz, DMSO-d6)
d0.95 (s, 9H); d1.79 (s, 2H); d3.69 (s, 3H); d3.82 (s, 6H); d6.08 (m,
1H); d6.57e6.60 (d, 1H); d6.92 (s, 2H); d7.12e7.14 (m, 1H);
d7.31e7.49 (m, 5H); d7.94 (s, 1H); d8.57 (s, 1H); d9.72 (s, 1H). 13C
NMR (DMSO, 100 MHz) d179.42; 164.98; 153.60; 139.92; 139.30;
130.93; 129.09; 124.75; 123.45; 122.06; 105.49; 60.62; 59.69;
56.35; 48.11; 30.24. MS 472.3 [MþH]þ. The results of 2D 13C, 1H
COSY(HMQC) spectra of compound 379 was shown in Table 6.
5.2.1.10. (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-
(3,4,5-trimethoxyphenyl)acrylamide (380). 1H NMR (400 MHz,erivatives with lapatinib in vitro toward BT474 cells.
Fig. 11. Coefﬁcient of drug interaction (CDI) of thiourea derivatives with lapatinib in vitro toward BT/LapR1.0 cells.
Y.-q. Zeng et al. / European Journal of Medicinal Chemistry 119 (2016) 83e9592CCl3D-d) d1.01 (s, 9H); d1.79e1.82 (m, 1H); d2.05 (m, 2H); d3.89 (s,
9H); d5.71 (s, 1H); d6.37e6.41 (d, 1H, J ¼ 15.44 Hz); d6.76 (m, 2H);
d7.02e7.04 (d, 1H, J ¼ 7.28 Hz); d7.31e7.34 (m, 1H); d7.67e7.71 (d,
1H, J ¼ 15.44 Hz); d8.24e8.26 (d, 1H, J ¼ 6.16 Hz); d8.42e8.43 (d,
1H); d8.83 (s,1H); d10.92 (s,1H). 13C NMR (DMSO,100MHz) d29.49;
29.74; 29.99; 55.71; 55.88; 60.13; 104.92; 105.23; 121.88; 123.35;
130.35; 136.28; 139.42; 144.25; 144.99; 153.11; 164.53; 179.54. MS
473.3 [MþH]þ.
5.2.1.11. (E)-N-(3,3-dimethyl-1-(3-pyridin-2-ylthioureido)butyl)-3-
(3,4,5-trimethoxyphenyl)acrylamide (381). 1H NMR (400 MHz,
CCl3D-d) d1.02 (s, 9H); d1.74 (s, 1H); d2.17e2.31 (m, 2H); d3.87 (s,
9H); d5.90 (s, 1H); d6.30e6.34 (d, 1H, J ¼ 15.68 Hz); d6.70e6.77 (m,
3H); d6.98e7.00 (t, 1H, J ¼ 6.44 Hz); d7.17 (s, 1H); d7.50e7.54 (d, 1H,
J¼ 15.68 Hz); d7.64e7.62 (t, 1H, J¼ 7 Hz); d8.25e8.26 (d, 1H); d8.43
(s, 1H); d12.39 (s, 1H). 13C NMR (DMSO, 100 MHz) d29.88; 30.07;
47.77; 55.88; 59.64; 60.12; 104.97; 112.66; 118.02; 121.45; 130.45;
139.09; 139.51; 145.65; 153.12; 153.73; 164.29; 178.07. MS 473.4
[MþH]þ.
5.2.1.12. 5.2.12. (E)-N-(2-methyl-1-(3-pyridin-2-ylureido)propyl)-3-
(3,4,5-trimethoxyphenyl) acrylamide (382). 1H NMR (400 MHz,
DMSO-d6) d0.95e0.99 (m, 6H); d2.21e2.24 (m, 1H); d3.68 (s, 3H);
d3.81 (s, 6H); d6.02e6.04 (m, 1H); d6.61e6.64 (d, 1H, J ¼ 15.68 Hz);
d6.90 (s, 2H); d7.08e7.12 (dd, 1H, J ¼ 6.44 Hz and 5.04 Hz);
d7.18e7.20 (d, 1H, J ¼ 8.4 Hz); d7.36e7.40 (d, 1H, J ¼ 15.68 Hz);
d7.78e7.80 (m, 1H); d8.24e8.25 (m, 1H); d8.50e8.52 (m, 1H,
J ¼ 7.84 Hz); d10.70 (s, 1H); d12.16e12.18 (d, 1H, J ¼ 8.12 Hz).
13CNMR (DMSO, 100 MHz) d17.72; 31.19; 55.82; 60.09; 65.49;
104.85; 112.73; 118.05; 139.19; 139.34; 145.62; 153.08; 153.74;
164.35; 179.49. MS 445.2 [MþH]þ.
5.2.1.13. (E)-N-(2-methyl-1-(3-phenylureido)propyl)-3-(3,4,5-
trimethoxy-phenyl) acrylamide (383). 1H NMR (400MHz, DMSO-d6)
d0.93e0.95 (m, 6H); d2.20 (m, 1H); d3.69 (s, 3H); d3.82 (s, 6H);
d5.86 (m, 1H); d6.78e6.80 (d, 1H); d6.92 (s, 2H); d7.11e7.13 (m, 1H);
d7.30e7.54 (m, 6H); d7.97 (s, 1H); d8.30 (m, 1H); d9.91 (m, 1H). MS
444.2 [MþH]þ.
5.2.1.14. 5.2.14. N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)cin-
namamide (384). 1H NMR (400 MHz, DMSO-d6) d0.93e0.95 (m,
6H); d1.91e2.29 (m, 4H); d3.68e3.71 (m, 1H); d3.82 (s, 6H);
d6.62e6.65 (d, 1H, J ¼ 16 Hz); d7.00e7.47 (m, 4H); d7.56e7.58 (m,
2H); d7.70e7.80 (m, 1H); d8.23e8.24 (m, 1H); d10.86e10.87 (m,
1H); d12.47e12.49 (m, 1H). 13C NMR (DMSO, 100 MHz) d21.54;
33.90; 45.93; 68.88; 112.84; 118.28; 119.50; 128.15; 128.84; 129.83;
134.87; 139.29; 141.31; 145.74; 153.59; 164.29; 177.40. MS 353.2
[MþH]þ.5.2.1.15. N-(3-methyl-1-(3-phenylthioureido)butyl)cinnamamide
(386). 1H NMR (400 MHz, DMSO-d6) d0.91e0.92 (m, 6H);
d1.67e1.73 (m, 3H); d6.03 (s, 1H); d6.66 (s, 1H); d7.10e7.13 (t, 1H);
d7.30e7.60 (m, 10H); d7.96 (s, 1H); d8.56 (s, 1H); d9.67 (s, 1H). MS
368.2 [MþH]þ.
5.2.1.16. N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)cinnamamide
(387). 1H NMR (400 MHz, DMSO-d6) d0.92e0.95 (m, 9H); d1.78 (m,
2H); d6.06 (s, 1H); d6.60e6.64 (d,1H); d7.10e7.13 (t, 1H); d7.31e7.57
(m, 10H); d7.97 (s, 1H); d8.65 (s, 1H); d9.71 (s, 1H). MS 382.2
[MþH]þ.
5.2.1.17. N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)cinnama-
mide (388). 1H NMR (400 MHz, DMSO-d6) d0.98 (m, 9H); d6.15 (s,
1H); d6.69e6.72 (d, 1H, J ¼ 13.44 Hz); d7.11e7.15 (t, 1H); d7.32e7.59
(m, 10H); d7.63e7.67 (d, 1H); d8.17 (s, 1H); d9.86 (s, 1H). 13CNMR
(DMSO, 100 MHz) d25.58; 36.47; 66.16; 121.82; 122.20; 122.92;
124.28; 127.56; 127.81; 128.55; 128.99; 129.53; 134.90; 139.13;
139.34; 165.93; 180.52. MS 368.2 [MþH]þ.
5.2.1.18. N-(cyclopropyl(3-phenylthioureido)methyl)cinnamamide
(389). 1H NMR (400 MHz, DMSO-d6) d1.89e2.19 (m, 4H);
d3.57e3.58 (m, 1H); d6.58e6.62 (t, 1H); d7.07e7.11 (t, 1H);
d7.20e7.54 (m, 10H); d7.69e7.71 (dd, 2H); d9.11 (d, 1H); d10.01 (s,
1H). MS 352.1 [MþH]þ.
5.2.1.19. N-(2-methyl-1-(3-phenylthioureido)propyl)cinnamamide
(390). 1H NMR (400 MHz, DMSO-d6) d0.92e0.94 (m, 6H); d2.22 (s,
1H); d5.83 (s, 1H); d6.70 (d, 1H); d7.09e7.13 (t, 1H); d7.31e7.58 (m,
10H); d7.85 (s, 1H); d8.43 (s, 1H); d9.77 (s, 1H). MS 354.1 [MþH]þ.
5.2.1.20. (E)-N-(3-methyl-1-(3-methylthioureido)butyl)-3-(3,4,5-
trimethoxy-phenyl)acrylamide (391). 1H NMR (400 MHz, DMSO-d6)
d0.94e0.97 (m, 7H); d1.66e1.70 (m, 3H); d2.93 (s, 3H); d3.75 (s,
3H); d3.78 (s, 6H); d5.95e5.99 (d,1H); d6.64e6.68 (d,1H, J¼ 16 Hz);
d6.97 (s, 2H); d7.47e7.52 (d, 1H, J ¼ 16 Hz); d8.01 (s, 1H); d8.74 (t,
1H). 13CNMR (DMSO, 100 MHz) d21.89; 22.45; 24.34; 31.44; 43.99;
58.84; 60.11; 105.00; 121.01; 130.33; 138.79; 141.21; 153.58;
166.22; 183.55. MS 396.3 [MþH]þ.
5.2.1.21. (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-
(3,4,5-trimethoxyphenyl)acrylamide (392). 1H NMR (400 MHz,
DMSO-d6) d0.94 (m, 9H); d2.19 (s, 3H); d3.68 (s, 3H); d3.81 (s, 6H);
d6.19 (s, 1H); d6.61e6.65 (d, 1H); d6.92 (s, 2H); d7.16e7.52 (m, 6H);
d8.61 (d, 1H); d9.46 (s, 1H). 13CNMR (DMSO, 100 MHz) d17.78;
25.54; 36.73; 55.82; 60.09; 66.37; 104.86; 121.73; 126.04; 126.34;
128.07; 130.36; 130.54; 134.48; 137.40; 138.58; 139.17; 153.08;
163.87; 181.75. MS 472.3 [MþH]þ.
Table 6
The results of 2D 13C, 1H COSY(HMQC) spectra of compounds 379, 405,397 and 407.
Assign. 379 405 397 407
dc (ppm) dH (ppm) dC (ppm) dH (ppm) dc (ppm) dH (ppm) dC (ppm) dH (ppm)
C1 105.49 6.92 104.96 6.95 128.92 7.41 128.84 7.41
C2 153.60 e 152.99 e 127.68 7.53 127.52 7.56
C3 130.5 e 130.43 e 134.35 7.21 134.58 7.58
C4 153.60 e 152.99 e 127.68 7.53 127.52 7.56
C5 105.49 6.92 104.96 6.95 128.92 7.41 128.84 7.41
C6 130.9 e 130.4 e 129.97 e 129.56 e
C7 139.3 7.35 138.72 7.44 140.93 7.55 139.40 7.50
C8 121 6.60 121.30 6.73 120.45 6.72 121.17 6,67
C9 164.98 e 164.45 e 166.20 165.14 e
C10 59.69 6.08 52.16 6.95 62.50 5.99 52.48 4.01
C11 179.42 e 181.00 e 178.89 e 179.33 e
C12 139.92 e 20.07 2.04 134.34 e 57.25 e
C13 123.45 7.49 24.27 1.7(A),
1.31(B)
139.01 e 24.28 1.65 (A),
1.22(B)
C14 129.09 7.33 32.15 1.92(C),
1.23(D)
129.87 7.19 31.82 1.85(C),
1.18(D)
C15 124.75 7.12 25.11 1.58(E),
1.23(D)
128.82 7.14 25.10 1.50(E),
1.18(D)
C16 129.09 7.33 32.15 1.92(C),
1.23(D)
125.73 7.15 24.28 1.65 (A),
1.22(B)
C17 123.45 7.49 24.27 1.7(A),
1.31(B)
126.23 7.12 31.82 1.85(C),
1.18(D)
C18 48.11 1.79 35.77 e 51.70 3.76 42.19 1.64
C19 30.25 0.96 25.38 0.89 33.04 2.13,2.00 32.20 1.21
C20 30.25 0.96 25.38 0.89 21.94 2.20,1.99 21.80 0.89
C21 30.25 0.96 25.38 0.89 17.49 2.14 21.80 0.89
C22 14.50 e 55.80 3.87
C23 56.35 3.82 59.99 3.74
C24 60.62 3.69 55.80 3.87
C25 56.35 3.82
Y.-q. Zeng et al. / European Journal of Medicinal Chemistry 119 (2016) 83e95 935.2.1.22. (E)-N-(cyclopropyl(3-o-tolylthioureido)methyl)-3-(3,4,5-
trimethoxyphenyl)acrylamide (393). 1H NMR (400 MHz, DMSO-d6)
d0.38e0.46 (m, 4H); d1.42 (s, 1H); d2.18 (s, 3H); d3.68 (s, 3H); d3.81
(s, 6H); d5.72 (s, 1H); d6.57e6.63 (d, 1H); d6.92 (s, 2H); d7.14e7.40
(m, 5H); d7.76 (s, 1H); d8.36 (s, 1H); d9.346 (s, 1H). MS 456.3
[MþH]þ.
5.2.1.23. N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide
(394). 1H NMR (400 MHz, DMSO-d6) d0.95 (m, 9H); d1.69e1.80 (m,
2H); d2.16 (s, 3H); d6.06 (s, 1H); d6.59e6.63 (d, 1H); d7.13e7.24 (m,
4H); d7.41e7.44 (m, 4H); d7.57e7.59 (d, 3H); d8.59 (s, 1H); d9.24 (s,
1H). 13CNMR (DMSO, 100 MHz) d180.10, 164.64, 139.29, 134.39,130.42, 129.63.129.01, 127.68, 126.42, 126.13, 122.96, 59.22, 48.01,
29.97, 29.68, 17.69. MS 395.9 [MþH]þ.
5.2.1.24. N-(3-methyl-1-(3-o-tolylthioureido)butyl)cinnamamide
(395). 1H NMR (400 MHz, DMSO-d6) d0.86e0.92 (m, 6H);
d1.24e1.25 (m, 1H); d1.67e1.68 (m, 2H); d2.16 (s, 3H); d6.05 (s, 1H);
d5.47e5.52 (s, 1H, NeH); d6.06 (s, 1H); d6.64e6.69 (m, 1H);
d7.15e7.18 (m, 4H); d7.41e7.43 (m, 3H); d7.58e7.59 (d, 2H); d8.47 (s,
1H); d9.20 (s, 1H) d9.95 (s, 1H, NeH). MS 381.5 [MþH]þ.
5.2.1.25. N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)cinnama-
mide (396). 1H NMR (400 MHz, DMSO-d6) d0.94 (m, 9H); d2.18 (s,
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4H); d7.57e7.59 (d, 2H); d8.19 (s, 1H). MS 382.1 [MþH]þ.
5.2.1.26. 5.2.26. N-(cyclopropyl(3-o-tolylthioureido)methyl)cinna-
mamide (397). 1H NMR (400 MHz, DMSO-d6) d1.97e2.00 (m, 2H);
d2.08e2.32 (m, 4H); d3.72e3.81 (m, 2H); d5.98e6.01 (t, 1H);
d6.71e6.75 (d, 1H, J ¼ 16 Hz); d7.15e7.16 (m, 4H); d7.40e7.43 (m,
3H); d7.53e7.60 (m, 3H); d9.10 (s, 1H); d9.62 (s, 1H). 13CNMR
(DMSO, 100 MHz) d17.49; 21.94; 33.04; 51.70; 60.09; 62.50; 120.45;
125.73; 126.32; 127.68; 128.82; 128.92; 129.87; 129.97; 134.35;
134.90; 139.01; 140.93; 166.20; 178.89. MS 366.2 [MþH]þ. The
results of 2D 13C, 1H COSY(HMQC) spectra of compound 397 was
shown in Table 6.
5 .2 .1.27 . (E) -N-(1-(3-(4-methoxyphenyl ) th ioure ido)-2-
methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (402). 1H NMR
(400 MHz, DMSO-d6) d0.91e0.98 (m, 6H); d2.18 (s, 1H); d3.68 (s,
3H); d3.74 (s, 3H); d3.81 (s, 6H); d5.86 (s, 1H); d6.60e6.64 (d, 1H);
d6.90e6.92 (d, 2H); d7.32e7.38 (m, 3H); d8.30 (s, 1H); d9.60 (s, 1H).
13C NMR (DMSO, 100 MHz) d18.12; 31.68; 55.23; 55.84; 60.11;
64.99; 104.96; 113.89; 125.50; 130.29; 130.59; 131.39; 138.68;
139.38; 153.07; 156.45; 164.55; 180.34. MS 474.2 [MþH]þ.
5.2.1.28. (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-
trimethoxyphenyl)acrylamide (404). 1H NMR (400 MHz, CCl3D-d)
d0.90e0.93 (m, 6H); d1.29e1.35 (m, 5H); d1.61e1.77 (m, 5H); d1.
92e2.15 (m, 2H); d3.89 (m, 9H); d4.09e4.11 (m, 1H); d5.44e5.48
(m, 1H); d6.19 (s, 1H); d6.47e6.51 (d, 1H); d6.76e6.85 (m, 2H);
d7.27e7.34 (d, 1H); d7.57e7.61 (d, 1H); d8. 27 (s, 1H). MS 464.4
[MþH]þ.
5.2 .1.29 . 5 .2 .29 . (E)-N-(1-(3-cyc lohexyl th ioureido)-2 ,2-
dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (405).
1H NMR (400 MHz, DMSO-d6) d0.89 (s, 9H); d1.20e1.31 (m, 7H);
d1.57e1.60 (d, 1H); d1.67 (s, 2H); d1.91 (s, 2H) d2.04 (s, 1H); d3.79 (s,
3H); d3.86 (s, 1H); d5.05e4.09 (m, 1H); d6.01e6.04 (s, 1H);
d6.67e6.74 (d, 1H); d6.95 (s, 2H); d7.21e7.25 (d, 1H); d7.24e7.26 (d,
1H); d7.42e7.45 (d, 1H); d7.68e7.70 (d, 1H); d8.16 (s, 1H). 13C NMR
(DMSO, 100 MHz) d181.00; 164.45; 152.99; 139.32; 138.72; 130.43;
121.30; 104.96; 65.50; 59.99; 59.61; 55.80; 52.16; 35.77; 32.15;
31.98; 25.38; 25.11; 24.27; 13.98. MS 464.4 [MþH]þ. The results of
2D 13C, 1H COSY(HMQC) spectra of compound 405 was shown in
Table 6.
5.2.1.30. (E)-N-(1-(3-cyclohexylthioureido)-2-methylpropyl)-3-
(3,4,5-trimethoxyphenyl)acrylamide (406). 1H NMR (400 MHz, -d)
d1.02e1.34 (m, 11H); d1.63e2.05 (m, 6H); d3.87e3.89 (m, 9H);
d4.09e4.11 (m, 1H); d5.14e5.18 (m, 1H); d6.17 (s, 1H); d6.55e6.59
(d, 1H); d6.74e6.78 (m, 2H); d7.57e7.61 (d, 1H); d8.02 (s, 1H). MS
450.2 [MþH]þ.
5.2.1.31. N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide
(407). 1H NMR (400 MHz, DMSO-d6) d0.88e0.89 (m, 6H);
d1.03e1.33 (m, 6H); d1.53e1.66 (m, 7H); d1.82e1.91 (m, 2H); d4.01
(s, 1H); d6.63e6.67 (d, 1H, J ¼ 15.68 Hz); d7.37e7.45 (m, 5H);
d7.48e7.52 (d, 1H, J ¼ 15.68 Hz); d7.56e7.62 (d, 2H, J ¼ 6.76 Hz);
d7.76 (s, 1H); d8.69 (s, 1H). 13CNMR (DMSO,100MHz) d21.80; 22.22;
24.24; 24.28; 25.10; 31.82; 32.20; 42.19; 52.48; 57.25; 121.17;
127.52; 128.84; 134.58; 139.40; 165.14; 179.33. MS 374.3 [MþH]þ.
The results of 2D 13C, 1H COSY(HMQC) spectra of compound 407
was shown in Table 6.
5.2.1.32. N-(1-(3-cyclohexylthioureido)-2-methylpropyl)cinnama-
mide (408). 1H NMR (400 MHz, DMSO-d6) d0.87e0.92 (m, 6H);
d1.10e1.29 (m, 6H); d1.56e1.87 (m, 5H); d2.12 (s, 1H); d3.98 (s, 1H);d6.68e6.72 (d, 1H); 7.39e7.44 (q, 4H); d7.57e7.66 (d, 2H). MS 360.3
[MþH]þ.
5.2.1.33. N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)cinna-
mamide (409). 1H NMR (400 MHz, DMSO-d6) d0.98e1.35 (m, 14H);
d1.57e2.10 (m, 5H); d4.10e4.12 (d, 1H); d5.19e5.24 (m, 1H); d5.61
(s, 1H); d6.03e6.05 (s, 1H); d6.47e6.59 (d, 1H); d7.35e7.38 (t, 2H);
d7.50e7.54 (d, 2H); d7.65e7.70 (d, 2H). 13C NMR (DMSO, 100 MHz)
d180.99; 164.67; 139.15; 134.85; 129.33; 128.82; 127.39; 122.03;
65.58; 52.10; 35.82; 32.14; 31.99; 25.37; 25.10; 24.24. MS 374.3
[MþH]þ.
6. Biological evaluations
6.1. Colorimetric determination of ATPase activity
The assay procedure was adopted from previous reports with
some modiﬁcations [26]where indicated. Stock solutions of mala-
chite green (0.1% w/v), polyvinyl alcohol (2.3% w/v), and ammo-
nium molybdate tetrahydrate (1% w/v in 1 M HCl) were prepared
and mixed with water at the ratio of 2:1:1:2 to prepare the mala-
chite green reagent, which is stable at room temperature for at least
2 h. After its colour changing from dark brown to yellow, the re-
agent should be ﬁltrated through a 0.22-mM ﬁltration membrane
prior to use. ATP, malachite green, polyvinyl alcohol and ammo-
nium molybdate tetrahydrate were purchased from SIGMA and
used without further puriﬁcation.
For compound screening, an aliquot of a master mixture of
DnaK:DnaJ (2.0 mM:3.5 mM) prepared in assay buffer (0.017% Triton
X-100, 100 mM TriseHCl, 20 mM KCl, and 6 mMMgCl2, pH 7.4) was
added into each well of a 96-well plate (14 mL per well). To this
solution, 1 mL of either one of the test compounds (5 mM) or DMSO
was added, and the plate was shaken for 10 min and incubated for
30 min at 37 C.
Ten microlitres of 2.5 mM ATP was added to start the reaction.
Thus, the ﬁnal reaction volume was 25 mL, and the concentration of
the tested compounds was 200 mM. After 3 h of incubation at 37 C,
80 mL of the malachite green reagent was added into each well, and
the plates were shaken gently. Immediately following this step,
10 mL of 34% sodium citrate was added to terminate the nonenzy-
matic hydrolysis of ATP. After the samples were mixed thoroughly
and incubated at 37 C for 15 min, the OD620 was measured using a
SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA).
6.2. Screening of resistance reversal agents
The breast cancer cell lines BT474 and BT/LapR1.0 were selected
for the in vitro evaluation of the cell viability and coefﬁcient of drug
interaction (CDI) of the thiourea derivatives. The epidermal growth
factor (EGFR: ErbB-1, ErbB-2) tyrosine kinase inhibitor lapatinib
(10mM in DMSO, BioVision, Cat: 1624-100, Lot: 50324) was used as
the positive control. The cell viability was measured using the
CellTiter-Glo® kit (Promega, Part: G755B, Lot: 32513501, EXP: 2014-
05). The cells were digested in 1 mL of 0.25% trypsin (Gibco) sup-
plemented with 2 mL of medium (containing 10% FBS, Gibco) and
seeded (1  105 cells/mL, 50 mL/well, 5000 cells/well) into 96-well
plates. The plates were incubated for 24 h at 37 C. The serially
diluted compounds and control were added into each well, and the
cells were incubated for 72 h at 37 C. A volume of the CellTiter-Glo
Reagent (50 mL) equal to the volume of the cell culture medium
present in each well was added. The plates were shaken for 3 min
on an orbital shaker to induce cell lysis. To stabilize the luminescent
signal, the platewas incubated at room temperature for 10min. The
luminescent signal was measured, and the datawere normalized to
that obtained for the control group. The cell viability was
Y.-q. Zeng et al. / European Journal of Medicinal Chemistry 119 (2016) 83e95 95determined based on the luminescence: cell viability
(%)¼ RLUexperimental group/RLUblank group 100%. Simultaneously, the
coefﬁcient of drug interaction (CDI) [25]was used to characterize
the interactions as synergism, additivity or antagonism: CDI ¼ AB/
(A  B)  100% (A, B and AB refer to the percentage inhibition
calculated by cell viability). If CDI< 1, the tested compounds
exhibited a synergistic effect with lapatinib, and signiﬁcant synergy
with lapatinib was deﬁned as CDI< 0.7.
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